...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Subtype-specific micro-RNA expression signatures in breast cancer progression
【24h】

Subtype-specific micro-RNA expression signatures in breast cancer progression

机译:乳腺癌进展中亚型特异性的微RNA表达特征

获取原文
获取原文并翻译 | 示例

摘要

Robust markers of invasiveness may help reduce the overtreatment of in situ carcinomas. Breast cancer is a heterogeneous disease and biological mechanisms for carcinogenesis vary between subtypes. Stratification by subtype is therefore necessary to identify relevant and robust signatures of invasive disease. We have identified microRNA (miRNA) alterations during breast cancer progression in two separate datasets and used stratification and external validation to strengthen the findings. We analyzed two separate datasets (METABRIC and AHUS) consisting of a total of 186 normal breast tissue samples, 18 ductal carcinoma in situ (DCIS) and 1,338 invasive breast carcinomas. Validation in a separate dataset and stratification by molecular subtypes based on immunohistochemistry, PAM50 and integrated cluster classifications were performed. We propose subtype-specific miRNA signatures of invasive carcinoma and a validated signature of DCIS. miRNAs included in the invasive signatures include downregulation of miR-139-5p in aggressive subtypes and upregulation of miR-29c-5p expression in the luminal subtypes. No miRNAs were differentially expressed in the transition from DCIS to invasive carcinomas on the whole, indicating the need for subtype stratification. A total of 27 miRNAs were included in our proposed DCIS signature. Significant alterations of expression included upregulation of miR-21-5p and the miR-200 family and downregulation of let-7 family members in DCIS samples. The signatures proposed here can form the basis for studies exploring DCIS samples with increased invasive potential and serum biomarkers for in situ and invasive breast cancer.
机译:强大的侵袭性标志物可能有助于减少原位癌的过度治疗。乳腺癌是一种异质性疾病,致癌作用的生物学机制因亚型而异。因此,有必要按亚型进行分层,以识别侵入性疾病的相关且可靠的特征。我们已经在两个独立的数据集中确定了乳腺癌进展过程中的microRNA(miRNA)改变,并使用分层和外部验证来加强发现。我们分析了两个单独的数据集(METABRIC和AHUS),包括总共186个正常乳腺组织样本,18个原位导管癌(DCIS)和1,338个浸润性乳腺癌。在一个单独的数据集中进行验证,并根据免疫组织化学,PAM50和综合簇分类按分子亚型进行分层。我们提出浸润性癌的亚型特异性miRNA签名和DCIS的经过验证的签名。包括在侵袭性标记中的miRNA包括侵略性亚型中miR-139-5p的下调和腔亚型中miR-29c-5p表达的上调。从DCIS到浸润性癌的过渡过程中,没有任何miRNA差异表达,这表明需要亚型分层。我们提议的DCIS签名中总共包括27个miRNA。表达的显着改变包括DCIS样品中miR-21-5p和miR-200家族的上调以及let-7家族成员的下调。这里提出的签名可以为探索具有增加的浸润潜力的DCIS样本和原位和浸润性乳腺癌血清生物标志物的研究奠定基础。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号